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cardiologists. Eighty-ﬁve percent of investigators were
afﬁliated with hospitals with over 101 beds. Sixty-ﬁve
percent and 72% of sites were public and teaching hos-
pitals, respectively. We found signiﬁcant variation among
physician/site characteristics across geographic regions.
Sixteen percent of US respondents were cardiologists,
52% in Latin America, 26% in Eastern Europe, 7% in
Europe, 4% in Africa and Asia Paciﬁc, and 0% in Canada
(p = <.0001). Twenty-nine percent of US investigators
were afﬁliated with public hospitals as compared to
100% in Canada, 97% in Eastern Europe, 88% in
Europe, 87% in Asia Paciﬁc, 53% in Latin America, and
22% in Africa (p = <.0001). CONCLUSION: We assessed
physician/site characteristics in a clinical trial setting and
determined that characteristics vary by geographic region.
Therefore, it is important to measure physician and site
characteristics to avoid the potential for confounding in
the economic evaluation of the NAVIGATOR trial.
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FACTORS INFLUENCING THE DIAGNOSTIC
TESTS PRESCRIBING FOR TYPE 2 DIABETES IN
AMBULATORY PATIENTS 
Rahman AM
St. John’s University, Jamaica, NY, USA
OBJECTIVES: Type 2 Diabetes is associated with severe
complications such as heart disease, stroke, high blood
pressure, kidney disease etc. Approximately 17 million
people suffer from diabetes accounting to 6.2% of the
population in the United States. According to the 
American Diabetes Association, the total cost of diabetes
to the society is 98 billion dollars. Type 2 diabetes
accounts for about 90–95% of all the diagnosed cases of
diabetes. This study examines the various physician and
patient factors, which inﬂuence the diagnostic test pre-
scribing for diabetes in ambulatory patients. METHODS:
Patient factors such as age, sex, race, geographical loca-
tion and payment source and Physician factors such as
specialty, geographic location and referral status were
used to determine their inﬂuence on the number of diag-
nostic tests prescribed. Data from the National Ambula-
tory Medical Care Survey (NAMCS) 2000 were utilized.
Patients with principal diagnosis of type 2 diabetes (ICD-
9-CM code 250.00) were analyzed using multiple linear
and binomial logit regression models. RESULTS: The
numbers of diagnostic tests performed were independent
of patients’ age, sex and geographic region (R2 = 0.117).
Blacks and Hispanic patients were prescribed more diag-
nostic tests compared to other races (R2 = 0.346).
Patients with Federal source of payments (Medicaid and
Medicare) were prescribed more diagnostic tests than
other patients (R2 = 0.245). Numbers of diagnostic tests
were not inﬂuenced by whether the patient was referred
(R2 = 0.037). Various physician specialties also had no
inﬂuence on the number of diagnostic tests prescribed (R2
= 0.054). CONCLUSIONS: The numbers of diagnostic
tests prescribed are signiﬁcantly inﬂuenced by patients’
race and source of payments. Diagnostic tests constitute
a signiﬁcant portion of the cost of diabetes therapy.
Further research, reviewing the causes of the signiﬁcant
differences seen in this study would help control/reduce
the cost of diabetes therapy.
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OBJECTIVES: A pharmacoeconomic analysis was
carried out comparing a long-acting analog of human
insulin, insulin glargine (once-daily injection), and NPH
human insulin (twice-daily injections) in patients with
Type 1 (DM1) and Type 2 (DM2) diabetes mellitus in
Spain. METHODS: Retrospective analysis using a cost-
offset model, from the perspective of the National Health
System in Spain. The following short term (1 year) health
costs of diabetes mellitus were used in the model: glargine
or NPH insulin treatment, use of lispro insulin, nurse
home visits, severe hypoglycemia episodes, test strips for
glucose control and disposable needles. The utilisation of
resources was estimated from two clinical trials compar-
ing insulin glargine (Lantus) and NPH human insulin in
patients with DM1 and DM2 and from Spanish sources,
and the unit costs from a Spanish health costs database.
RESULTS: The use of glargine insulin instead of NPH
insulin would result in an annual saving of €234.75 and
€89.47 for a patient with DM1 and DM2, respectively.
Although the acquisition cost of glargine insulin is higher,
yearly savings can be achieved compared to NPH insulin
in the remaining costs analysed especially in the use of
less test strips (€198.85 in DM1 and DM2), less costs in
nurse home visits (€83.22 in DM1 and DM2), lower
doses of lispro insulin (€49.78 in DM1), lower incidence
of severe hypoglycemia (€6.91 and €1.33 in DM1 and
DM2) and lower costs in insulin needles (5.02 euros in
DM1 and DM2). CONCLUSIONS: A comprehensive
analysis of the costs associated with insulin treatment
shows that switching to once-daily insulin glargine from
NPH insulin reduces Health System costs for treating
Type 1 and Type 2 diabetic patients in Spain.
DIABETES—Quality of Life/Preference Based
Outcomes
PDB26
EVALUATION OF QUALITY OF LIFE IN
PATIENTS WITH NEUROPATHY USING THE
NORFOLK QUALITY OF LIFE (QOL) TOOL
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OBJECTIVE: Our objective was to examine the scores
and reproducibility of a 47 item Quality Of Life ques-
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tionnaire (Norfolk QOL) previously constructed using
the Delphi method to inventory neuropathy subscales:
symptoms, involvement of small, large, autonomic nerve
ﬁbers, and activities of daily living (ADL). METHODS:
We studied 242 subjects comprising three groups: 75
healthy control (C); 86 diabetic control without neu-
ropathy (DC); and 81 diabetic patients with peripheral
neuropathy (DN). The questionnaire was administered to
all three groups and repeated at 1–3 month intervals to
determine scores, reliability and reproducibility. One-way
analysis of variance (ANOVA) and Tukey-Kramer post
hoc (= 0.05) tests were used to compare the different
groups and Cronbach alpha coefﬁcients of internal con-
sistency and intra-class correlation coefﬁcients (ICC) to
test reproducibility. RESULTS: Overall the DN group
(39.8 ± 3.3) scored 3–4 fold higher than DC (12.8 ± 1.5)
and 6–10 fold higher than C (5.8 ± 1.0). Scores for each
subscale were <1–5.1 in C and 1.3–11.2 in DC whereas
DN scores were: autonomic 4.0 ± 0.3; small ﬁber 8.3 ±
0.7; large ﬁber 11.3 ± 1.1 and ADL 31.6 ± 2.8 (p < 0.05
for all). DC scored higher than C because of urinary 
problems in females and erectile dysfunction in non-
neuropathic males. ADLs were worse in DC because of
diabetes and its complications other than neuropathy
accounting for the feeling of accomplishing less. All items
met the requirements of a Cronbach alpha coefﬁcient of
internal consistency >0.5 and ICC r > 0.9. CONCLU-
SIONS: The Norfolk QOL domains and individual items
are reproducible in all groups. This instrument is sensi-
tive and speciﬁc for the different features of diabetic neu-
ropathy and has the capacity for providing non-invasive
clinical guidelines for assessing disease impact and for
evaluating responses to treatment.
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OBJECTIVE: The purpose of this study is to quantify and
compare diabetes patient preferences for short-term treat-
ment outcomes and the number insulin injections among
Type 2 patients in the US and Canada. METHODS: A
total of 1931 subjects with Type 2 diabetes completed a
stated-preference questionnaire that included a series of
12 hypothetical treatment choices. Each treatment alter-
native speciﬁed the number of daily insulin injections,
fasting plasma glucose (FPG), glycated hemoglobin
(HbA1c), number of hypoglycemic events per month, and
monthly cost of treatment. RESULTS: Patients in both the
US and Canada place signiﬁcant value on reducing the
number of daily insulin injections and improving glucose
control. US patients value avoiding an increase from 1
injection to 2 injections at about US$60 per month. 
Canadian patients value avoiding the same change in
injections at about 60% lower at US$25. Both US and
Canadian patients value improving their current glucose
control to the best level as equivalent to an income gain
of about $30 per month. CONCLUSIONS: Type 2 dia-
betes patients in both the US and Canada value better
glucose control and fewer injections. Canadian patients
value improved control more than fewer injections. In
contrast, US patients value fewer injections almost twice
as much as improved control. While all patients are
willing to sacriﬁce glucose to avoid injections, US patients
are more likely than Canadian patients to do so. Insulin
delivery devices that reduce the burden of injections are
likely to be preferred by Type 2 patients. Given the serious
long-term health risks associated with poor glucose
control, less burdensome insulin delivery methods that
also result in greater compliance have the potential to
improve long-term health outcomes among Type 2
patients.
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OBJECTIVES: As insulin delivery products evolve, it
becomes important to identify patients’ expectations
about these products to satisfy their perceived needs. The
purpose of this study was to develop a self-administered
questionnaire for use in subsequent evaluations of expec-
tations and satisfaction with an insulin injection pen.
Expectations of products and subsequent experience lead
to consumers’ satisfaction and other outcome measures.
In this phase of instrument development a closely related
notion, preference, was used as a surrogate for satisfac-
tion since the data were collected prior to product expe-
rience. METHODS: Development of the instrument
included item generation, item reduction and analysis to
assess reliability and validity. A questionnaire consisting
of 49 items was generated for the initial phase of this
study. Using an expert panel and focus groups, items were
evaluated for content and face validity to ensure they ade-
quately represented expectations. The sample consisted of
1500 United States residents randomly selected from a
mail address database containing respondents known to
have types 1 or 2 diabetes. We used a single mailing, 
consisting of a cover letter, data collection instrument 
and return envelope. RESULTS: The response rate was
20.4%. Kaiser-Meyer-Olkin (KMO) Measure of Sam-
pling Adequacy for the ﬁnal principal components analy-
sis was 0.92. Bartlett Test of Sphericity was signiﬁcant
(.0001), indicating the appropriate use of exploratory
factor analysis. Item reduction was accomplished by
examining item-to-total correlations and factor loadings.
Oblique rotation was used to obtain a ﬁnal factor solu-
